| Ytd | -20.30% | |
| 1y | 21.78% |
| Open | 28.05 | Prev Close | 27.67 | Low | 27.51 | High | 28.23 | Mkt Cap | 3.27B |
| Vol | 555.01K | Avg Vol | 1.28M | EPS | -1.96 | P/E | -14.27 | Forward P/E | -27.71 |
| Beta | 0.08 | Short Ratio | 6.98 | Inst. Own | 106.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 32.13 | 200-d Avg | 33.80 | 1yr Est | 49.84 |
NAMS News
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.52 per share versus the
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrap
NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
/PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS oder „NewAmsterdam" oder das „Unterne
NewAmsterdam Pharma offers differentiated potential with obicetrapib, targeting comprehensive cardio
/PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS (ou « NewAmsterdam » ou la « Société
/PRNewswire/ -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"),
- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetra
NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conf
NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 202
NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis P
NewAmsterdam Pharma NASDAQ: NAMS said it plans to conduct an interim analysis of its ongoing PREVAIL
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.4 per share versus the
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo